MegaPro Biomedical Co (6827.TWO) Stock Price

MegaPro Biomedical Co Price

CLOSED
14.95
​
Market closed

Revenue at MegaPro Biomedical Co has contracted by 79.2% per year over the past 4 years to 14,000.00 TWD. For MegaPro Biomedical Co, the net margin of -1,171,721.4% is down versus -2,003.8% a few years ago.

MegaPro Biomedical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MegaPro Biomedical Co business model & stock analysis

MegaPro Biomedical Co., Ltd. generates revenue through its development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's primary products are MPB-1514, MPB-1523, MPB-1734, and MPB-2043, each targeting specific medical conditions. MPB-1514 treats anemia in chronic kidney disease patients via intravenous injection, while MPB-1523 diagnoses hepatocellular carcinoma through intravenous administration. MPB-1734 addresses solid tumors with intravenous treatment, and MPB-2043 aids in diagnosing metastases in peripheral lymph nodes of cancer sites. These products are sold to healthcare providers and medical institutions requiring advanced diagnostic and therapeutic solutions. The company focuses on two core technology platforms: nanoparticle and nanocell, which underpin its product development. Its product portfolio targets chronic kidney disease, hepatocellular carcinoma, solid tumors, and cancer metastasis diagnostics. These applications are directed toward medical professionals and facilities specializing in oncology and nephrology. The firm's revenue model relies on the commercialization of these specialized drug ingredients for targeted medical treatments and diagnostics. MegaPro Biomedical's products are designed for intravenous use across various medical conditions, positioning the company within the biotechnology sector. Its revenue streams come from the sale of these proprietary drug ingredients to hospitals, clinics, and research institutions. The company's market segments include healthcare providers treating kidney disease, cancer diagnostics, and oncology-focused medical facilities seeking innovative therapeutic solutions.

Frequently asked questions about MegaPro Biomedical Co

Converted at the current exchange rate, the MegaPro Biomedical Co share trades at 0.41 EUR (14.95 TWD).

The revenue cannot currently be calculated for MegaPro Biomedical Co.

The profit cannot currently be calculated for MegaPro Biomedical Co.

The P/E ratio cannot be calculated for MegaPro Biomedical Co at the moment.

The P/S cannot be calculated for MegaPro Biomedical Co currently.

The Eulerpool Quality Score for MegaPro Biomedical Co is 2/10.

The ISIN of MegaPro Biomedical Co is TW0006827009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of MegaPro Biomedical Co is 6827.TWO. The ticker symbol is used to trade MegaPro Biomedical Co shares on the stock exchange.

Fair ValueTerminal
13.01 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Oct 19, 2021
ISIN
TW0006827009
Cusip
Y5S33F109
Market capitalization
1.19 B TWDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
4.52
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-45.35 %
Last updated Nov 11, 2026, 11:33 PM

MegaPro Biomedical Co Peer Group

MegaPro Biomedical Co FIGI

6827:TT (Taipei Stock Exchange) · BBG012WH5CQ1